Quest Diagnostics Incorporated (DGX) — ESG & Values Scores

Environment story

Quest Diagnostics discloses minimal quantitative environmental data in its 10-K filings. No Scope 1, 2, or 3 emissions figures are provided, and no net-zero target date is disclosed. The company mentions general sustainability initiatives (energy efficiency, pollution prevention, fleet conservation, resource conservation) but these lack specificity, quantification, or verification. A significant 2024 California Attorney General settlement ($undisclosed penalty) related to unlawful disposal of hazardous waste, medical waste, and protected health information at company facilities represents a material environmental and operational compliance failure. The company's reliance on general sustainability language without concrete metrics, targets, or third-party verification suggests potential greenwashing. Absence of disclosed Scope 3 emissions is a critical gap for a laboratory testing company dependent on supply chains and logistics. No evidence of substantive decarbonization investments or renewable energy commitments is disclosed.

Criticisms on file

2024 California AG Settlement: Unlawful Disposal of Hazardous Waste, Medical Waste, and Protected Health Information. Quest paid penalty for improper disposal at company facilities.
Source: DGX Proxy Statement (Proposal 4, Stockholder Proposal); 2024 California Attorney General enforcement action
2019 Data Breach via Third-Party Vendor (AMCA): 12 million patients' personal, medical, and financial information exposed. Litigation ongoing as of 2025 alleging failure to properly safeguard patient information and ensure vendor security.
Source: DGX Proxy Statement (Proposal 4, Stockholder Proposal); 10-K Risk Factors regarding third-party vendor cybersecurity incidents

Disclosed initiatives

Energy Efficiency & Fleet Conservation

General initiatives to conserve resources and minimize negative environmental impact through energy efficiency, fleet conservation, and pollution prevention.

Unquantified; no baseline, targets, or third-party verification disclosed.
Strategic Sourcing

Mentioned as part of sustainability efforts but no details provided.

Social story

Quest Diagnostics reports approximately 70% female workforce representation globally, indicating above-average gender diversity in a healthcare testing context. However, the company discloses no quantitative data on executive/board-level leadership diversity, no CEO-to-median-worker pay ratio, no documented union suppression or major strikes within 24 months, and no supply-chain human-rights audits specific to high-risk geographies (DRC cobalt, lithium, etc.). The proxy disclosures note 'good' employee relations overall, but the 10-K acknowledges unionization activity risk, labor recruitment constraints, and competition for qualified personnel. No evidence of unmitigated supply-chain labor abuses is disclosed, though the company's reliance on specimen logistics and international operations (Canada, Europe) creates exposure. Board and executive leadership diversity metrics are not quantified in disclosed documents. The company mentions a $100 million-plus charitable initiative to reduce health disparities and operates a Quest Community Action Network volunteer program, indicating some social commitment but limited quantification of outcomes.

Criticisms on file

2019 Data Breach Ongoing Litigation: 12 million patients exposed through third-party vendor (AMCA). Lawsuits allege inadequate vendor security oversight and patient data safeguarding failure. Litigation ongoing in 2025.
Source: DGX Proxy Statement (Proposal 4, Stockholder Proposal); 10-K Risk Factors section on data privacy and third-party vendor breaches
Malpractice Litigation: Company regularly cited in legal information resources (law firm websites) as defendant in malpractice lawsuits related to alleged lab errors and diagnostic failures, some with severe patient outcomes.
Source: DGX Proxy Statement (Proposal 4, Stockholder Proposal)
Drug Testing False Positives in California Prisons: Guardian investigation reported that Quest Diagnostics' drug tests used in California correctional facilities yielded thousands of potential false positives over an extended period. Data analysis suggested >5,000 false positives; expert assessment that high positivity rates rendered tests 'basically worthless,' raising systemic quality and patient/public safety concerns.
Source: DGX Proxy Statement (Proposal 4, Stockholder Proposal); The Guardian investigation

Disclosed initiatives

$100 Million-Plus Health Disparities Initiative

Quest Diagnostics and the Quest Diagnostics Foundation launched a multi-year initiative to help reduce health disparities in underserved American communities (launched 2020).

Unquantified; no metrics on beneficiaries, outcomes, or funding allocation disclosed.
Patient Assistance Program

Tailored solutions for uninsured or underinsured patients based on individual circumstances.

No quantification of patient volume, assistance provided, or outcomes disclosed.
Environment, Health and Safety Program

Program designed to reduce risk of employee and patient injury.

Unquantified; no injury rates, incident metrics, or improvement trends disclosed.
Employee Volunteer Program - Quest Community Action Network

Chapters across the country help raise awareness and funds for worthwhile causes.

No participation metrics or charitable outcomes disclosed.
Matching Gifts & Employee Relief Fund

Matching Gifts programs provide funds to nonprofit organizations; Employee Relief Fund assists charitable-class employees following unforeseen hardship.

No quantification of funds distributed or employees assisted disclosed.

Governance story

Quest Diagnostics maintains a majority-independent board (10 of 11 directors independent; only CEO James E. Davis is non-independent). Board independence is strong at approximately 91%, exceeding the 75% threshold. The company has implemented numerous governance best practices: annual director elections, majority voting standard, lead independent director role, no dual-class share structure, no 'poison pill' provision, stockholder proxy access, right to request special meetings, and right to act by written consent. However, governance concerns exist. The company combines Chairman and CEO roles under James E. Davis (Chairman since April 2023, CEO since November 2022), which was the subject of a 2026 stockholder proposal seeking separation. The Board rejected the proposal, asserting flexibility is necessary. No quantified corporate political spending is disclosed in the 10-K or proxy for climate-regulation or consumer-protection lobbying. The company acknowledges 'Corporate Political Contributions Policy' is available on its website but does not disclose specific lobbying expenditures or policy stances in SEC filings. Antitrust and regulatory proceedings are noted as ongoing risks in the 10-K, with multiple references to qui tam (whistleblower) claims, government investigations, billing compliance litigation, and potential exclusion from Medicare/Medicaid programs, but no active material proceedings are detailed. The company has not been sued by shareholders to block climate proposals. Overall, structural governance is strong; transparency on political spending and active regulatory matters is limited.

Criticisms on file

Combined Chairman/CEO Role: James E. Davis holds both Chairman and CEO positions (Chairman since April 2023, CEO since November 2022). A 2026 stockholder proposal (Proposal 4) requested separation of roles and appointment of independent Chairman. Board rejected proposal, citing need for flexibility. Approximately 78% of S&P 500 companies provide separation or designated Lead Independent Director per Board response.
Source: DGX Proxy Statement, Proposal 4 (Stockholder Proposal) and Board Response; 2026 Annual Meeting materials
Ongoing Regulatory Risk & Qui Tam Exposure: 10-K details extensive risk of government investigations, qui tam (whistleblower) claims, billing compliance litigation, and potential Medicare/Medicaid exclusion. Federal and state governments noted as having 'substantial leverage' in settlement negotiations due to potential damages exceeding reimbursement rates.
Source: DGX 10-K, Risk Factors: 'We are subject to numerous legal and regulatory requirements...'; 'Failure to accurately bill for our services...'; litigation and settlement risk discussion
2024 California Attorney General Enforcement: Settlement for unlawful disposal of hazardous waste, medical waste, and protected health information at Quest facilities. Penalty imposed but amount not disclosed in SEC filings reviewed.
Source: DGX Proxy Statement (Proposal 4, Stockholder Proposal); 2024 California Attorney General enforcement action
2019 Data Breach Third-Party Vendor Failure (AMCA): 12 million patients' data exposed through American Medical Collection Agency vendor. Lawsuits ongoing as of 2025 alleging inadequate vendor security oversight. Reflects governance failure in third-party risk management.
Source: DGX Proxy Statement (Proposal 4); 10-K Risk Factors section on cybersecurity and third-party vendor breaches

Disclosed initiatives

Lead Independent Director Role

Timothy M. Ring serves as Lead Independent Director with clearly defined role and robust responsibilities including chairing executive sessions of independent directors.

Provides independent oversight and check on CEO/Chairman power concentration.
Cybersecurity Committee of the Board

Dedicated board committee (established 2019) oversees cybersecurity and data security policies, plans, programs, practices, and risks. Reviews legal/regulatory compliance and industry standards related to IT security.

Addresses material cybersecurity and data privacy risks in a healthcare data context.
Board Risk Oversight

Enterprise Risk Management program driven by executive leadership; Audit and Finance Committee oversees risk assessment and management. Board reviews program at least annually.

Systematic identification and mitigation of material risks.
Annual Say-on-Pay Vote

Stockholders vote annually on executive compensation in advisory (non-binding) vote.

Provides shareholder voice on pay alignment with performance.
Stockholder Engagement & Proxy Access

Company actively engages with stockholders; proxy access rights enable shareholders to nominate directors; stockholders can request special meetings and act by written consent.

Enhances stockholder governance participation.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Quest Diagnostics Incorporated. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Quest Diagnostics Incorporated in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)